BUZZ-Viking Therapeutics' oral obesity drug meets mid-stage study goal, shares fall
Reuters
Aug 19
BUZZ-<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' oral obesity drug meets mid-stage study goal, shares fall
** Shares of drug developer Viking Therapeutics VKTX.O fall 18% to $33.96 premarket
** Co says its experimental oral obesity drug, VK2735, showed statistically significant reductions in body weight compared with placebo and was safe and well-tolerated through 13 weeks of daily dosing
** Co says the drug helped patients lose 12.2% of their body weight on average over 13 weeks
** Analysts ahead of the results had expected weight loss in the range of 10% to 15% on average and greater than the 8.2% seen in a small early-stage trial
** Co says 13% of participants receiving placebo discontinued treatment due to side effects, compared with 20% of participants receiving VK2735
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.